Ocular Surface and Dry Eye Center, Is.Pre Oftalmica, 16129 Genoa, Italy.
Ocular Surface and Dry Eye Center, ASST Fatebenefratelli-Sacco, Ospedale Sacco-Università di Milano, 20157 Milan, Italy.
Int J Mol Sci. 2023 Jan 11;24(2):1458. doi: 10.3390/ijms24021458.
Dry eye disease (DED) is a multifactorial condition resulting from reduced tear secretion from the lacrimal glands, increased tear water evaporation or the production of poor-quality tears. Such tear instability can lead to inflammation and damage of the ocular surface, as well as to abnormal nociception. Historically, tear substitutes and corticosteroids have been the bastion of DED therapy, but a substantial number of patients still suffer from residual symptoms even after being treated with traditional treatments. Aiming to find safe and effective alternative therapies, recent efforts have been focused on the role of vitamin D in the cellular physiology of the eye. Possibly because of its positive effect in modulating the immune and inflammatory responses, the systemic supplementation of vitamin D seems, indeed, to be an effective therapeutic strategy, especially, but not only, for patients affected by DED that does not respond to conventional treatments. In this context, this review focuses on the literature reporting on the pathogenesis and treatment of DED, with a special emphasis on the recent investigations reporting on the potential role of the systemic administration of vitamin D as a therapeutic approach in the management of such condition.
干眼症(DED)是一种多因素疾病,由泪腺分泌减少、泪液蒸发增加或产生质量差的泪液引起。这种泪液不稳定会导致眼表面的炎症和损伤,以及异常的痛觉。从历史上看,人工泪液和皮质类固醇一直是DED 治疗的基础,但即使经过传统治疗,仍有相当数量的患者仍有残留症状。为了寻找安全有效的替代治疗方法,最近的研究重点关注了维生素 D 在眼睛细胞生理学中的作用。可能由于其在调节免疫和炎症反应方面的积极作用,全身性维生素 D 补充似乎确实是一种有效的治疗策略,特别是但不仅限于对传统治疗方法无效的 DED 患者。在这种情况下,本综述重点关注了关于 DED 的发病机制和治疗的文献,特别强调了最近关于全身性维生素 D 给药作为治疗方法在管理这种疾病中的潜在作用的研究报告。